



## ATTACHMENT A

### Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently amended) A monoclonal An isolated antibody that can bind to the propeptide of the Int1p protein of *Candida albicans* wherein the propeptide consists of having the amino acid residues 1-263 of the amino acid sequence of SEQ ID NO:1, that has the ability to prevent cleavage of the propeptide from the Int1p protein, and that has the ability to inhibit T lymphocyte activation caused by *Candida albicans*.
2. (Canceled)
3. (Canceled)
4. (Previously Presented) Isolated antisera containing the antibody according to Claim 1.
5. (Withdrawn) A method of treating or preventing an infection by a microorganism expressing the Int1p protein comprising administering an effective amount of the antibody according to claim 1 to a human or animal patient.

6. (Withdrawn) A method according to claim 5 wherein the microorganism is selected from the group consisting of *Candida albicans* and *Saccharomyces cerevisiae*.

7. (Withdrawn) A method according to claim 5 wherein the antibody is raised to a portion of the propeptide of Int1p effective to generate an immune response.

8. (Withdrawn) A method for treating patients exposed to *Candida albicans* in the presence of heparin, the method comprising:

administering the antibody according to claim 1 to a human or animal patient in an amount effective to bind with the heparin and to reduce or eliminate the activation of the Int1p protein.

9. (Previously Presented) A pharmaceutical composition comprising the isolated antibody according to claim 1 and a physiologically acceptable carrier, vehicle or diluent.

10. (Canceled)

11. (Previously Presented) A diagnostic kit comprising the antibody according to claim 1 and means for detecting binding by that antibody.

12. (Canceled)

13. (Canceled)

14. (Canceled)

15. (Canceled)

16. (Withdrawn) A method of treating or preventing an infection by a microorganism expressing the Int1p protein comprising administering an effective amount of the antibody according to claim 12 to a human or animal patient.

17. (Canceled)

18. (Withdrawn) An isolated peptide selected from the group consisting of the propeptide region at amino acids 1-263, the Catalytic domain 1 at amino acids 435-639, the Catalytic domain 2 at amino acids 738-949, and the Processing domain motif at amino acids 1022-1236 of the amino acid sequence depicted in Fig. 1.

19. (Withdrawn) A method of generating an antibody comprising introducing a peptide according to claim 18 in a host capable of generating antibodies thereto.

20. (Withdrawn) An isolated nucleic acid sequence coding for the peptide according to claim 18.

21. (Withdrawn) A method of inducing an immunological response comprising administering to a patient a peptide according to claim 18.

22. (Withdrawn) A vaccine comprising a peptide according to claim 18 in an amount effective to generate an immunological response.

23. (Canceled).

24. (Withdrawn) A method of diagnosing an infection by a microorganism capable of expressing an Int1p protein comprising introducing an antibody according to claim 12 into a sample suspected of having an infection by an Int1p-producing microorganism and determining the binding of said antibody to said sample.

25. (Withdrawn) A method according to claim 24 wherein the microorganism is selected from the group consisting of *Candida albicans* and *Saccharomyces cerevisiae*.

26. (Withdrawn) A method of treating or preventing infections caused by microorganisms expressing the Int1p protein comprising administering an effective amount of an agent that inhibits Int1p activity.

27. (Withdrawn) A method according to claim 26 wherein the agent modulates a peptide region or motif from the Int1p protein which is involved in the pathway of activation for the Int1p protein.

28. (Withdrawn) A method according to claim 26 wherein the agent modulates a peptide selected from the group consisting of the propeptide region at amino acids 1-263, the Catalytic domain 1 at amino acids 435-639, the Catalytic domain 2 at amino acids 738-949, and the Processing domain motif at amino acids 1022-1236 of the amino acid sequence depicted in Fig. 1.

29. (Withdrawn) A method according to claim 26 wherein the microorganism is a yeast of the *Candida* species.

30. (Withdrawn) A method according to claim 26 wherein the microorganism is selected from the group consisting of *Candida albicans* and *Saccharomyces cerevisiae*.

31. (Currently amended) The monoclonalisolated antibody according to claim 1 wherein said antibody is capable of inhibiting T lymphocyte activity in a host cell.

32. (Currently amended) The isolatedmonoclonal antibody according to claim 31 wherein the host cell is selected from the group consisting of epithelial and endothelial cells.